Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

June 30, 2008

Conditions
Leukemia
Interventions
DRUG

temozolomide

Trial Locations (16)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University, New York

13210

SUNY Upstate Medical University Hospital, Syracuse

15213

Children's Hospital of Pittsburgh, Pittsburgh

38105

St. Jude Children's Research Hospital, Memphis

55455

Fairview University Medical Center - University Campus, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

94305

Stanford Cancer Center at Stanford University Medical Center, Stanford

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

46202-5289

Indiana University Cancer Center, Indianapolis

39216-4505

University of Mississippi Medical Center, Jackson

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

19104-9786

Children's Hospital of Philadelphia, Philadelphia

77030-2399

Baylor University Medical Center - Houston, Houston

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

Hopital Sainte Justine, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00083070 - Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia | Biotech Hunter | Biotech Hunter